A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia.
This study aimed to evaluate the cost and effectiveness of introducing a live, attenuated vaccine (SA 14-14-2) against Japanese encephalitis (JE) into the immunization program. The study demonstrated that SA 14-14-2 immunization is cost-effective in controlling JE in Cambodia compared to no vaccination. Averting one disability-adjusted life year, from a societal perspective, through the introduction of SA 14-14-2 through routine immunization, or a combination of routine immunization plus a campaign targeting children 1-5 or 1-10 years of age, costs US$22, US$34 and US$53, respectively. Sensitivity analyses confirmed that there was a high probability of SA 14-14-2 immunization being cost-effective under conditions of uncertainty.
Touch
Sok
S
Communicable Disease Control Department, Ministry of Health, Cambodia. chhanly@yahoo.com
Suraratdecha
Chutima
C
Samnang
Chham
C
Heng
Seng
S
Gazley
Lauren
L
Huch
Chea
C
Sovann
Ly
L
Chhay
Chab Seak
CS
Soeung
Sann Chan
SC
D000293:Adolescent; D002160:Cambodia; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004672:Encephalitis, Japanese / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D022321:Japanese Encephalitis Vaccines / Q000191:economics*; D014613:Vaccines, Attenuated / Q000191:economics
D022321:Japanese Encephalitis Vaccines; D014613:Vaccines, Attenuated